BridgeMD
Compares treatment options for Angina
Official title LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions
ClinicalTrials.gov ID: NCT05786417
What this study is testing
What is Beta blocker?
Beta blocker is an investigational medicine, being studied as a potential treatment for angina.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 65 and older
You may be able to join if
- OLDER ADULTS WITH SIHD AND MCC
- Age ≥65 years
- ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS)
- Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following:
- positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease
You likely can't join if
- OLDER ADULTS WITH SIHD AND MCC
- Current taking (both) a beta-blocker AND a calcium channel blocker\
- Contraindication to beta-blockers or calcium channel blockers including:
- significant hypotension
- high grade AV block
- severe symptomatic bradycardia
See the full eligibility criteria
- OLDER ADULTS WITH SIHD AND MCC
- Age ≥65 years
- ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS)
- Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following:
- positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease
- coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or ≥50% stenosis of left main
- Invasive coronary angiography with positive physiologic testing in at least one vessel (FFR ≤ 0.80 or iFR ≤0.89) CAREGIVERS
- Age ≥ 18 years
- Identified as caregiver of LIVEBETTER participant
- OLDER ADULTS WITH SIHD AND MCC
- Current taking (both) a beta-blocker AND a calcium channel blocker\
- Contraindication to beta-blockers or calcium channel blockers including:
- significant hypotension
- high grade AV block
- severe symptomatic bradycardia
- severe obstructive lung disease
- Documented intolerance to beta-blockers or calcium channel blockers
- Probable or definite high-risk coronary artery disease including unrevascularized left main disease and/or unrevascularized multi-vessel disease including the proximal left anterior descending (LAD) artery with plans...
- Plans for complete revascularization within 2 weeks
- Clear clinical indication for beta-blockers or calcium channel blockers that precludes dose adjustment or crossover:
- Diagnosis of acute coronary syndrome (ACS) with reduced ejection fraction within past year
- Heart failure with reduced ejection fraction (HFrEF) within past year
- Actively participating in another clinical trial involving an investigational medication or device
- Primary language other than English or Spanish
- Inability to complete follow-up (e.g. life expectancy \<12 months, impaired decision-making determined by validated instrument)
- Previously enrolled in LIVEBETTER
- Refused informed consent CAREGIVERS
- Professional caregiver (i.e. not a relative or close friend of the participant)
- Primary language other than English or Spanish
- Inability to complete follow-up
- Previously enrolled in LIVEBETTER
- Refused informed consent
The study team makes the final eligibility decision.
Where it's taking place
- New Haven, Connecticut, United States
- Marietta, Georgia, United States
- Chicago, Illinois, United States
- Boston, Massachusetts, United States
- New York, New York, United States
- Durham, North Carolina, United States
- Cleveland, Ohio, United States
- Fairfax, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Haven, Connecticut, United States; Marietta, Georgia, United States; Chicago, Illinois, United States; Boston, Massachusetts, United States; New York, New York, United States; Durham, North Carolina, United States and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.